ArticlePediatric rheumatology online journal2013

Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis.

Gabriele Simonini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.